"Take a Closer Look", page-1094

Agreed. In the second half of 2016 a few of us were saying "Let's not throw the baby out with the bath water, I'll wait till the Feb HY report to assess my position and make a call" (or something to that effect).... under the old guard, it may have been a tragic outcome, but what a fantastic report it was. Ticked all the right boxes to show that the turnaround we so desperately needed was in fact happening. Let's face it, anyone who purchased prior to code red did so on the hope that management would unlock the value of our IP and deliver benefits to shareholders. Anyone who purchased POST the Feb HY report did so with proof in hand that management were unlocking and delivering value. I fell into both camps - but I'm pleased to say that purchases were far more heavily weighted to the post Feb HY report. WP et al are delivering the goods and it's an incredibly exciting time to be an Admedus holder. Can't wait for the FY17 report, and hopefully FY18 guidance by the AGM.